CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research (NCT07313059) | Clinical Trial Compass
RecruitingNot Applicable
CHAPTER: Clonal Haematopoiesis Assessment: Prevention, Treatment and Research
Australia100 participantsStarted 2026-03-20
Plain-language summary
People identified to have CH or thought to have possible CH due to unexplained low blood cell counts, including low red blood cells, white blood cells, or platelets will be asked to take part in the study.
Individuals who are confirmed to have CH and provide informed consent to participate in the study will have monitoring of their CH, assessment of the risk of heart diseases, blood cancers and personalised support. The researchers will also measure people's understanding of CH and how they feel after learning about CH.
Researchers will then record the relevant information from people with CH in a central database over time to track long-term health outcomes.
The information collected from the study will help create a blueprint for doctors to provide care for people with CH in the future, and guide further research into CH in Australia.
Participants will be asked to donate blood samples for the study for research purposes including CH monitoring and testing and also provide health information for the central database.
Who can participate
Age range
55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Aged 55 years and above
. Confirmed CH or possible CH, with possible CH defined by:
. Provision of written informed consent prior to any study-related assessments or procedures being carried out.
Exclusion criteria
. Severe cytopenia as defined by one or more of the following:
. ANC \< 0.5 x109/L
. Hb \< 80 g/L
. Platelet count \< 50 x 109/L
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Establishment of CH participant registry and characterisation of CH outcomes
Timeframe: Through study completion, 5 years
Trial details
NCT IDNCT07313059
SponsorClinical Hub for Interventional Research (CHOIR)